<?xml version="1.0" encoding="UTF-8"?>
<p>Further we attempted to dock GS-441524 (active form of remdesivir) and hydrochloroquine, which are being repurposed for treating COVID-19. The rational for including these molecules is that their principle inhibitory mechanism takes place inside the host cell where viral replication unfolds. The possibility for these molecules to bind to offâ€“target proteins that are of viral or host origin cannot be ruled out. Recently FDA has issued an Emergency Use Authorization (EUA) for remdesivir to be included in treatment protocol of hospitalized SARS-CoV-2 infected patients (Rhoades, 
 <xref rid="CIT0037" ref-type="bibr">2020</xref>).
</p>
